There are presented compounds of the formula
or pharmaceutically acceptable salts thereof,
wherein Y
1
, Y
2
, X
1
, X
2
, X
3
and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.